Brief Communication abstract
Nature Medicine 15, 873 - 875 (2009)
Published online: 20 July 2009 | doi:10.1038/nm.1991
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
Kara L O'Brien1, Jinyan Liu1, Sharon L King1, Ying-Hua Sun1, Joern E Schmitz2, Michelle A Lifton2, Natalie A Hutnick3, Michael R Betts3, Sheri A Dubey4, Jaap Goudsmit5, John W Shiver4, Michael N Robertson4, Danilo R Casimiro4 & Dan H Barouch1,6
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
- Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
- Merck Research Laboratories, West Point, Pennsylvania, USA.
- Crucell Holland BV, Leiden, The Netherlands.
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.
Correspondence to: Dan H Barouch1,6 e-mail: dbarouch@bidmc.harvard.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine?induced expansion of adenovirus-specific CD4 + T cellsNature Medicine Brief Communication (01 Aug 2009)
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature Letters to Editor (01 Jan 2009)
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunityNature Letters to Editor (11 May 2006)
See all 20 matches for Research
